| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20015001 | HPV | ENSG00000120217.14 | protein_coding | CD274 | Yes | No | 29126 | Q9NZQ7 |
| TVIS20063337 | HPV | ENSG00000120217.14 | protein_coding | CD274 | Yes | No | 29126 | Q9NZQ7 |
| TVIS20063338 | HPV | ENSG00000120217.14 | protein_coding | CD274 | Yes | No | 29126 | Q9NZQ7 |
| TVIS20063339 | HPV | ENSG00000120217.14 | protein_coding | CD274 | Yes | No | 29126 | Q9NZQ7 |
| TVIS20063340 | HPV | ENSG00000120217.14 | protein_coding | CD274 | Yes | No | 29126 | Q9NZQ7 |
| TVIS20015000 | HPV | ENSG00000120217.14 | protein_coding | CD274 | Yes | No | 29126 | Q9NZQ7 |
| TVIS20020581 | HPV | ENSG00000120217.14 | protein_coding | CD274 | Yes | No | 29126 | Q9NZQ7 |
| TVIS20034037 | HPV | ENSG00000120217.14 | protein_coding | CD274 | Yes | No | 29126 | Q9NZQ7 |
| TVIS20034033 | HPV | ENSG00000120217.14 | protein_coding | CD274 | Yes | No | 29126 | Q9NZQ7 |
| TVIS20034034 | HPV | ENSG00000120217.14 | protein_coding | CD274 | Yes | No | 29126 | Q9NZQ7 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CD274 |
|---|---|
| DrugBank ID | DB11595 |
| Drug Name | Atezolizumab |
| Target ID | BE0003441 |
| UniProt ID | Q9NZQ7 |
| Regulation Type | inhibitor |
| PubMed IDs | 27412122; 26952546; 33807678 |
| Citations | Markham A: Atezolizumab: First Global Approval. Drugs. 2016 Aug;76(12):1227-32. doi: 10.1007/s40265-016-0618-8.@@Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4.@@Kyriakidis I, Vasileiou E, Rossig C, Roilides E, Groll AH, Tragiannidis A: Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. J Fungi (Basel). 2021 Mar 5;7(3). pii: jof7030186. doi: 10.3390/jof7030186. |
| Groups | Approved; Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
